Clinical trials: Cholangiocarcinoma Cancer
Biliary Tract Cancer
Allogeneic NK Cell ("SMT-NK") in Combination With Pembrolizumab in Advanced Biliary Tract Cancer
The term of biliary tract cancer (BTC) or cholangiocarcinoma refers to all tumors that arise from the biliary tract or the biliary drainage system, including the gallbladder.
- Trial name
- NCT03937895
- Testing
- 'SMT-NK' Inj (allogeneic Natural Killer cell), Pembrolizumab Injection [Keytruda]
- Where
- 2 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- SMT bio Co., Ltd.
Cholangiocarcinoma
Study on the Accuracy of Proteomics in Evaluating Lymph Node Metastasis Status in Cholangiocarcinoma Patients
This is a single-center, prospective, observational and exploratory clinical study. The object of this study is to evaluate the accuracy of proteomics approaches on resected lymph node samples in evaluating lymph node metastasis…
- Trial name
- NCT05721963
- Testing
- No interventions.
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Pancreatic Cancer, Small Bowel Cancer
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
The objective of this expanded access program is to provide ulixertinib (BVD-523) for compassionate use in advanced cancer patients with MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF…
- Conditions
- Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer, Melanoma
- Trial name
- NCT04566393
- Testing
- Ulixertinib (BVD-523)
- Where
- 26 sites in United States
- Sponsor
- xCures
Cholangiocarcinoma, Gall Bladder Carcinoma
Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection
This prospective, open-Label, comparative, randomized, controlled phase III trial was designed to compare the clinical performance of gemcitabine with capecitabine vs.
- Trial name
- AdBTC-1 (NCT03779035)
- Testing
- Gemcitabine, Capecitabine
- Where
- China
- Volunteers
- 460 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
This is an open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4859 in adult…
- Conditions
- Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult, FGFR2 Gene Fusion/Rearrangement
- Trial name
- NCT06777316
- Testing
- CGT4859
- Where
- 13 sites in United States, Canada
- Volunteers
- 110 people
- Sponsor
- Cogent Biosciences, Inc.
Hepatocellular Carcinoma, Cholangiocarcinoma
A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer
This is an open label, multi-center, phase II study of BBI503 administered to adult patients with advanced hepatobiliary cancer who have exhausted all currently approved standard anti-cancer treatment options.
- Trial name
- NCT02232633
- Testing
- BBI503
- Where
- 3 sites in Canada
- Volunteers
- 45 people
- Sponsor
- Sumitomo Pharma America, Inc.
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
This phase II trial is studying how well lapatinib works in treating patients with locally advanced or metastatic biliary tract or liver cancer that cannot be removed by surgery.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00101036
- Testing
- lapatinib ditosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
Intrahepatic Cholangiocarcinoma
A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma
This is a single-arm, open-label, multi-center Phase II clinical trial intended to observe and evaluate the efficacy and safety of famitinib malate in treating iCCA(Intrahepatic Cholangiocarcinoma ) patients with FGFR2 genetic…
- Trial name
- NCT04479904
- Testing
- Famitinib
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Cholangiocarcinoma
Comparison of Biliary Forceps Biopsy and Brush Cytology
Cholangiocarcinomas (CCCs) are malignant tumors arising from the biliary epithelium. CCCs are characterised by a high mortality and the only curable therapy is complete tumor resection, if feasible, or in some cases liver…
- Trial name
- NCT01145248
- Testing
- double-balloon enteroscopy forceps biopsy, Transpapillary brush cytology
- Where
- Germany
- Volunteers
- 43 people
- Sponsor
- University of Ulm
Malignant Mesothelioma, Colorectal Cancer
Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
This is a first-in-human, single-arm, open-label, dose escalation clinical study to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics, immunogenicity and preliminary efficacy of UCMYM802…
- Conditions
- Malignant Mesothelioma, Colorectal Cancer, Bile Duct Cancer, Rectal Cancer
- Trial name
- NCT06256055
- Testing
- UCMYM802 Injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- UTC Therapeutics Inc.
Pancreatic Cancer
ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer
The goal of this clinical trial is to learn if total removal of the pancreas is a preferable alternative to partial removal in patients with cancer of the pancreatic head who are at high risk of pancreatic leakage.
- Trial name
- ToPanc (NCT06801899)
- Testing
- Total pancreatectomy (TP), Partial pancreaticoduodenectomy (PD)
- Where
- 10 sites in Germany, Switzerland
- Volunteers
- 170 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Cholangiocarcinoma
Single Arm Study of RAD001 as Monotherapy in Treatment in Advanced Cholangiocarcinoma
The purpose of this study is to determine whether everolimus is effective in the treatment of patients with advance cholangiocarcinoma.
- Trial name
- CRAD001T (NCT01525719)
- Testing
- Everolimus
- Volunteers
- 40 people
- Sponsor
- Ratchavithi Hospital
Liver Carcinoma, Hepatocellular Carcinoma
Combined HCC-MFCCC
Combined hepatocellular and mass-forming cholangiocarcinoma (cHCC-MFCCC) is a rare tumor. The aim of this study was the analysis of the outcome comparing such tumor with classic hepatocellular carcinoma (HCC) and mass-forming…
- Conditions
- Liver Carcinoma, Hepatocellular Carcinoma, Cholangiocarcinoma, Surgery
- Trial name
- NCT03178409
- Testing
- Hepatectomy
- Volunteers
- 100 people
- Sponsor
- University of Milan
Advanced Solid Tumor, Unresectable Solid Tumor
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
This study is researching whether the combination of Afatinib and Pemigatinib is safe and effective in FGFR altered unresectable or metastatic advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Cholangiocarcinoma
- Trial name
- NCT06302621
- Testing
- Afatinib, Pemigatinib
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Massachusetts General Hospital
Hepatocellular Carcinoma, Cholangiocarcinoma
Changes in Liver Function After Stereotactic Body Radiation Therapy Measured by PET/CT
Patients treated with stereotactic radiotherapy for liver tumors undergo PET/CT using the galactose analogue 18-F-deoxy-galactose (FDGal) before and after radiotherapy.
- Conditions
- Hepatocellular Carcinoma, Cholangiocarcinoma, Metastases, Stereotactic Body Radiotherapy
- Trial name
- NCT01213758
- Testing
- Measuring liver function by PET/CT
- Where
- Denmark
- Volunteers
- 14 people
- Sponsor
- University of Aarhus
Cholangiocarcinoma, Surgery--Complications
Long-term Morbidity After Surgery for Perihilar Cholangiocarcinoma
Surgery for perihilar cholangiocarcinoma offers the only possibility of long-term survival, but remains a formidable undertaking.
- Trial name
- NCT03999593
- Testing
- Resection of perihilar cholangiocarcinoma
- Volunteers
- 60 people
- Sponsor
- University of Liverpool
Advanced Solid Tumor, Cholangiocarcinoma
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Cholangiocarcinoma, HER2-negative Breast Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04742959
- Testing
- TT-00420, Nab-Paclitaxel
- Where
- 6 sites in United States
- Volunteers
- 203 people
- Sponsor
- TransThera Sciences (Nanjing), Inc.
Acinar Cell Carcinoma, Ampulla of Vater Adenocarcinoma
WASH Trial: Intraoperative Lavage as a Treatment for Pancreatic Cancer
The goal of this clinical trial is to learn if a special washing treatment used during surgery can help people with pancreatic cancer live longer.
- Conditions
- Acinar Cell Carcinoma, Ampulla of Vater Adenocarcinoma, Cholangiocarcinoma, Duodenal Adenocarcinoma
- Trial name
- NCT02757859
- Testing
- Pancreatectomy, Lavage
- Where
- United States
- Volunteers
- 845 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Advanced Cholangiocarcinoma
Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma
Cholangiocarcinoma (CCA) is a heterogeneous group of cancers arising from the epithelial cells of bile ducts. Because of highly aggressive malignancy, most of the patients are diagnosed at an advanced stage and lose the chance to…
- Trial name
- NCT05532059
- Testing
- Lenvatinib, tislelizumab, gemcitabine and cisplatin, gemcitabine and cisplatin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Cholangiocarcinoma
Clinical Trial of Autologous Tcm Immunotherapy in ICC
The prime purpose of this trial is to evaluate the Progression Free survival and two-year survival of combining autologous Tcm cellular immunotherapy and traditional therapy in intrahepatic cholangiocarcinoma (ICC) patients after…
- Trial name
- NCT03820310
- Testing
- autologous Tcm cellular immunotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Newish Technology (Beijing) Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.